Teva Pharmaceuticals has presented new real-world evidence showing that deutetrabenazine — marketed as AUSTEDO and its extended-release formulation AUSTEDO XR — delivered measurable improvements in both symptom management and quality-of-life outcomes for patients living with Huntington's disease (HD) chorea. The data were unveiled at the Advanced Therapeutics in Movement & Related Disorders Congress in Washington, D.C., running June 4–8, 2026.
The findings come from what Teva describes as the first and only real-world, decentralized study to capture patient- and caregiver-reported impacts of HD chorea alongside the therapeutic effect of deutetrabenazine. Investigators tracked improvements across multiple quality-of-life measures, with results indicating that effective chorea management translated directly into broader functional gains for both patients and their caregivers. Deutetrabenazine works as a vesicular monoamine transporter 2 (VMAT2) inhibitor, selectively reducing the excess dopaminergic signaling that drives involuntary choreiform movements — a mechanism distinct from general dopamine-receptor blockade and associated with a more targeted tolerability profile.
While AUSTEDO is an FDA-approved prescription therapy rather than a dietary supplement or nutraceutical, the study's decentralized design and its explicit focus on patient-reported outcomes and caregiver burden are methodological signals increasingly relevant to the broader functional health market. Sponsors of condition-specific wellness products — including those targeting neurological and movement-related health claims — are under growing pressure from retailers and payers alike to produce real-world evidence, not just double-blind, placebo-controlled trial data. The HD chorea category remains a rare-disease space, but the outcomes framework employed here mirrors what finished-formulation developers in the nootropic and neuro-wellness segments are being asked to replicate at scale. For context on how patient-centered endpoints are reshaping supplement substantiation standards, see our coverage of emerging clinical-trial design in nutraceuticals and neuro-wellness ingredient positioning.
Teva, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) headquartered in Parsippany, N.J., continues to expand its neurology data package as competition in the VMAT2 inhibitor class intensifies. The decentralized study format — allowing participants to enroll and report outcomes remotely — also reflects a broader industry shift toward pragmatic trial designs that capture diverse, community-based populations rather than highly controlled clinic cohorts. This approach is gaining traction across both pharmaceutical and nutraceutical research as sponsors seek evidence that travels beyond the lab and into real-world care settings.
This coverage is produced in partnership with Food & Beverage Magazine, part of the F&B Network.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.